Signaturefd LLC Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Signaturefd LLC trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 26.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,700 shares of the medical research company’s stock after selling 2,010 shares during the period. Signaturefd LLC’s holdings in Edwards Lifesciences were worth $376,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences during the 1st quarter worth $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $29,000. Webster Bank N. A. purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $39,000. Versant Capital Management Inc boosted its position in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares during the period. Finally, HHM Wealth Advisors LLC purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $55,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

EW opened at $69.38 on Friday. The firm has a market cap of $41.81 billion, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company’s 50-day moving average price is $68.08 and its 200 day moving average price is $78.65. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EW. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Truist Financial decreased their price objective on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research report on Friday. Citigroup decreased their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Finally, Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $75.67.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,250 shares of company stock worth $1,099,238. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.